RxDoctor Payments Data

James Throneberry, MD

Family Medicine · Conway, ARNPI 1316949308

Payments from drug & device makers

$9,751in general payments, 2019–2025

Across 613 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Pfizer$1K
  • Lilly USA, LLC$854
  • AbbVie$839
  • GSK$536
  • Novo Nordisk$493
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,69099%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,751 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$388,942
Medicare patients
633
Services billed
7,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin144$138,717
FarxigaDapagliflozin Propanediol102$67,051
EliquisApixaban40$46,878
OzempicSemaglutide35$33,014
XareltoRivaroxaban24$21,335
RybelsusSemaglutide18$21,073
MounjaroTirzepatide22$20,224
JanuviaSitagliptin Phosphate21$19,780
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog34$15,129
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$13,783
Tresiba Flextouch U-100Insulin Degludec25$13,421
EntrestoSacubitril/Valsartan13$10,027
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$8,471
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,921
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$255$138,717144 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,806$74,972115 claims
Novo NordiskOzempic, Rybelsus$493$54,08853 claims
PfizerEliquis$1,013$46,87840 claims
MerckJanuvia, Janumet Xr$161$25,63532 claims
Johnson & JohnsonXarelto$256$21,33524 claims
Lilly USA, LLCMounjaro$854$20,22422 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$536$16,22635 claims
NovartisEntresto$139$10,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →